E
Sell
11/4/2024Upgraded
Telomir Pharmaceuticals, Inc. (TELO) was upgraded to E+ from E on 11/4/2024 due to an increase in the growth index, total return index and volatility index. Earnings per share increased from -$0.2252 to -$0.0489, EBIT increased 23.05% from -$1.92M to -$1.47M, and operating cash flow increased 21.48% from -$1.94M to -$1.52M.
E
Sell
8/1/2024Upgraded
Telomir Pharmaceuticals, Inc. (TELO) was upgraded to E from E- on 8/1/2024 due to a major increase in the solvency index, growth index and total return index. The quick ratio increased from 0 to 7, debt to equity declined from 0.18 to 0, and earnings per share increased from -$0.326 to -$0.2252.
E
Sell
5/7/2024None
Telomir Pharmaceuticals, Inc. (TELO) was downgraded to E- from U on 05/07/2024.
